- Developing lead product MAT9001 to treat cardiovascular and metabolic conditions
- Conducting Phase 2 head-to-head study of MAT9001 versus FDA-approved rival Vascep
- Flush with $71.2 million in cash to fund clinical studies and operations into 2022
What Matinas BioPharma does:
Matinas BioPharma Holdings (NYSEAMERICAN:MTNB) is a clinical-stage biopharmaceutical company focused on the development of its lead product candidate MAT9001 for the treatment of cardiovascular and metabolic conditions.
The Bedminster, New Jersey-based company is also working on the advancement of its proprietary lipid nano-crystal (LNC) platform technology for the safe delivery of therapies previously limited by toxicity or bioavailability issues.
MAT9001 is a prescription-only omega-3 fatty acid-based formulation, comprised primarily of EPA and DPA (both essential polyunsaturated fatty acids), under development for the specific treatment of hypertriglyceridemia. Triglycerides are a type of fat in human blood, and having too many can lead to heart disease or acute pancreatitis.
In addition, Matinas is developing MAT2203, an oral-delivered formulation of Amphotericin-B, to treat serious invasive fungal infections. The drug is based on the company’s LNC platform and has the potential to substantially improve an otherwise challenging safety profile in critically ill patients.
How is it doing:
Matinas is well-capitalized to fund operations for the next three years. In fact, it has $71.2 million in cash thanks to a $50 million registered public offering, giving the company a long runway to further the development of its flagship drugs -- MAT9001 and MAT2203.
WIth MAT9001, Matinas has commenced enrollment and started dosing patients in its much-anticipated Phase 2 ENHANCE-IT study, following a two-month pause due to the coronavirus (COVID-19) outbreak and related business shutdowns.
It is a head-to-head study versus Amarin Corporation PLC's Vascepa, the only drug approved by the US Food and Drug Administration that’s designed to fight high triglyceride levels. The study will determine how effectively both drugs reduce triglyceride levels and other important lipid markers, in addition to gathering data on bioavailability and omega-3 fatty acids in the blood.
MAT9001 and Vascepa will each be administered twice daily to a target of 100 enrolled patients over two 28-day treatment periods. The company will end enrollment in August 2020 and expects topline results from the study in the first quarter of 2021.
The company said ENHANCE-IT builds on an earlier study comparing MAT9001 with Vascepa that “provided significantly greater reductions in PD (pharmacodynamic) markers known to be associated with increased risk of cardiovascular disease, including triglycerides.”
Matinas’ senior managers are confident that MAT9001 is superior to Vascepa in reducing serum triglycerides and cholesterol. They are also not worried about generic versions of the rival drug that could hit the market following a US District Court ruling in March that invalidated some of Amarin patents protecting the drug.
When it comes to protecting MAT9001, Matinas believes that the drug, if approved by the US Food & Drug Administration (FDA), will be eligible for five-year New Chemical Entity exclusivity and subject to the Hatch Waxman Amendments, which could prevent generic alternatives for more than seven years.
But FDA approval is ways off. The company already is preparing to hold an End-of-Phase 2 meeting with the agency in the third quarter of 2020 while laying the groundwork for a Phase 3 registration study in patients with severe hypertriglyceridemia. Again it will go up against Vascepa. Approval hangs on successful outcomes in both studies.
To further MAT9001’s development and eventual commercialization the company recently appointed James A Underberg to its scientific advisory board. He is director of the Bellevue Hospital Lipid Clinic and a clinical assistant professor of medicine at the NYU School of Medicine and NYU Center for Prevention of Cardiovascular Disease.
MAT2203 EnAct Study
As for MAT2203, the company is moving ahead with the antifungal drug’s development as well. In Uganda, Matinas is currently running Part 2 of its EnACT study of the drug as a treatment for HIV patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immuno-compromised patients.
The open-label, sequential cohort study, financially sponsored by the National Institutes of Health (NIH), applies Matinas’ LNC drug delivery technology to orally deliver amphotericin B, an otherwise IV-only, highly toxic drug. Oral MAT2203 is designed to target delivery directly to infected tissues, protecting the body from unnecessary exposure to amphotericin B with a lower propensity for kidney toxicity.
Part 1 demonstrated that MAT2203 was safe and well-tolerated across three different daily dosing regimes. Part 2 is a randomized trial evaluating the safety, tolerability, and efficacy of MAT2203 in patients, compared to treatment with standard IV-administered amphotericin B.
The FDA has designated MAT2203 as a Qualified Infectious Disease Product with Fast Track status for four indications: The prevention of invasive fungal infections due to immuno-suppressive therapy as well as the treatment of invasive candidiasis, invasive aspergillus, and cryptococcal meningitis. In addition, the FDA granted orphan drug designation to MAT2203 for the treatment of cryptococcosis.
- Expects topline results from ENHANCE-It study in 1Q 2021
- Anticipates End-of-Phase 2 meeting with FDA on MAT9001 in 3Q 2020
- Planning Phase 3 clinical program of MAT9001 to treat severe hypertriglyceridemia
- Expects data from NIH-funded EnAct study of MAT2203 in 1H 2021
- Expects first fully enrolled cohort of EnAct patients by early September 2020
What the boss says:
"MAT9001’s potential position as best-in-class prescription-only omega-3 continues to be contingent on, among other things, the results of the planned ENHANCE-IT study and the outcome of our potential Phase 3 clinical program in severe hypertriglyceridemia," Matinas BioPharma CEO Jerome Jabbour has said.
"We are excited to have the opportunity to let the data speak for themselves and we look forward to building upon the existing data for MAT9001 which demonstrates superiority to Vascepa, and therefore to any generic alternative to Vascepa.”